A pragmatic diagnostic approach to primary intracranial germ cell tumors and their treatment outcomes.

Q1 Medicine

CNS Oncology Pub Date : 2021-11-22 DOI:10.2217/cns-2021-0012

Jeyaanth Venkatasai, Rajesh Balakrishnan, Balakrishnan Rajkrishna, Patricia Sebastain, Rikki Rorima John, Harshad Arvind Vanjare, Krishna Prabhu, Bijesh Nair, Leni Grace Mathew, Selvamani Backianathan

{"title":"A pragmatic diagnostic approach to primary intracranial germ cell tumors and their treatment outcomes.","authors":"Jeyaanth Venkatasai, Rajesh Balakrishnan, Balakrishnan Rajkrishna, Patricia Sebastain, Rikki Rorima John, Harshad Arvind Vanjare, Krishna Prabhu, Bijesh Nair, Leni Grace Mathew, Selvamani Backianathan","doi":"10.2217/cns-2021-0012","DOIUrl":null,"url":null,"abstract":"Background: Primary intracranial germ cell tumors (ICGCT) are often diagnosed with tumor markers and imaging, which may avoid the need for a biopsy. An intracranial germ cell tumor with mild elevation of markers is seldom stratified as a distinct entity. Methods: Fifty-nine patients were stratified into three groups: pure germinoma (PG), secreting germinoma (SG) and non-germinomatous germ cell tumors (NGGCTs). Results: At 5 years, progression-free survival and overall survival of the three groups (PG vs SG vs NGGCT) were 91% versus 81% versus 59%, and 100% versus 82% versus 68%, respectively. There was no statistically significant difference in outcome among histologically and clinically diagnosed germinomas. Conclusion: A criterion for clinical diagnosis when a biopsy is not feasible is elucidated, and comparable outcomes were demonstrated with histologically diagnosed germinomas.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/0f/cns-10-79.PMC8610002.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2021-0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Primary intracranial germ cell tumors (ICGCT) are often diagnosed with tumor markers and imaging, which may avoid the need for a biopsy. An intracranial germ cell tumor with mild elevation of markers is seldom stratified as a distinct entity. Methods: Fifty-nine patients were stratified into three groups: pure germinoma (PG), secreting germinoma (SG) and non-germinomatous germ cell tumors (NGGCTs). Results: At 5 years, progression-free survival and overall survival of the three groups (PG vs SG vs NGGCT) were 91% versus 81% versus 59%, and 100% versus 82% versus 68%, respectively. There was no statistically significant difference in outcome among histologically and clinically diagnosed germinomas. Conclusion: A criterion for clinical diagnosis when a biopsy is not feasible is elucidated, and comparable outcomes were demonstrated with histologically diagnosed germinomas.

查看原文本刊更多论文

颅内原发性生殖细胞瘤的实用诊断方法及其治疗效果。

背景：原发性颅内生殖细胞瘤（ICGCT）通常通过肿瘤标志物和影像学检查来诊断，这样可以避免活检。标记物轻度升高的颅内生殖细胞瘤很少作为一个独立实体进行分层。方法：将59名患者分为三组：纯生殖细胞瘤（PG）、分泌性生殖细胞瘤（SG）和非生殖细胞瘤（NGGCTs）。结果显示5年后，三组（PG vs SG vs NGGCT）的无进展生存率和总生存率分别为91%对81%对59%，以及100%对82%对68%。组织学诊断和临床诊断的生殖细胞瘤之间的结果差异无统计学意义。结论：在无法进行活组织检查的情况下，临床诊断的标准得到了阐明，组织学诊断的生殖细胞瘤的疗效相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS Oncology Medicine-Neurology (clinical)

CiteScore

3.80

自引率

0.00%

发文量

审稿时长

13 weeks